Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension

E-poster session
Chairs: V. Mercurio (Napoli, Italy), O. Sitbon (Le Kremlin-Bicêtre, France)

Precapillary pulmonary hypertension in patients with a high HFpEF probability: Insights from the Amsterdam UMC PAH-cohort A. Kianzad (Amsterdam, Netherlands), F. De Man (Amsterdam, Netherlands), L. Celant (Amsterdam, Netherlands), A. Vonk Noordegraaf (Amsterdam, Netherlands), L. Handoko (Amsterdam, Netherlands), H. Bogaard (Amsterdam, Netherlands)
A Minimal Clinically Important Difference for CAMPHOR in Idiopathic Pulmonary Arterial Hypertension K. Bunclark (Cambridge (Cambridgeshire), United Kingdom), N. Doughty (Cambridge (Cambridgeshire), United Kingdom), A. Michael (Cambridge (Cambridgeshire), United Kingdom), N. Abraham (Cambridge (Cambridgeshire), United Kingdom), S. Ali (Cambridge (Cambridgeshire), United Kingdom), J. Cannon (Cambridge (Cambridgeshire), United Kingdom), K. Sheares (Cambridge (Cambridgeshire), United Kingdom), N. Speed (Cambridge (Cambridgeshire), United Kingdom), D. Taboada (Cambridge (Cambridgeshire), United Kingdom), M. Toshner (Cambridge (Cambridgeshire), United Kingdom), J. Pepke-Zaba (Cambridge (Cambridgeshire), United Kingdom)
Assessment of quality of life and social and economic impact of the disease in patients with pulmonary arterial hypertension in Germany – Data of the SANTANA-Study J. Fuge (Hannover, Germany), M. Richter (Gießen, Germany), H. Gall (Gießen, Germany), A. Ghofrani (Gießen, Germany), M. Hoeper (Hannover, Germany), K. Olsson (Hannover, Germany)
Lung perfusion in pulmonary hypertension – results from the RESPIRE study P. Hughes (Sheffield, United Kingdom), A. Swift (Sheffield, United Kingdom), F. Wilson (Stevenage, United Kingdom), M. Cogliano (Sheffield, United Kingdom), F. Alandejani (Sheffield, United Kingdom), A. Cahn (Stevenage, United Kingdom), L. Kendall (Stevenage, United Kingdom), D. Kiely (Sheffield, United Kingdom), J. Wild (Sheffield, United Kingdom)
Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities P. Xanthouli (Heidelberg, Germany), M. Kögler (Heidelberg, Germany), A. Marra (Naples, Italy), N. Benjamin (Heidelberg, Germany), L. Fischer (Heidelberg, Germany), C. Eichstaedt (Heidelberg, Germany), S. Harutyunova (Heidelberg, Germany), C. Nagel (Heidelberg, Germany), E. Grünig (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany)
Risk assessment, therapy and cardiovascular comorbidity in patients with pulmonary arterial hypertension K. Swinnen (Leuven, Belgium), M. Delcroix (Leuven, Belgium), R. Quarck (Leuven, Belgium), C. Dewachter (Brussels, Belgium), J. Vachiéry (Brussels, Belgium), C. Belge (Leuven, Belgium)
Cardiac MRI right atrial area measurement thresholds for risk stratification in patients with PAH F. Alandejani ( Sheffield, United Kingdom), E. Tubman ( Sheffield, United Kingdom), Y. Shahin ( Sheffield, United Kingdom), R. Lewis ( Sheffield, United Kingdom), K. Dwivedi ( Sheffield, United Kingdom), D. Alkhanfar ( Sheffield, United Kingdom), S. Alabed ( Sheffield, United Kingdom), C. Johns ( Sheffield, United Kingdom), P. Garg ( Sheffield, United Kingdom), R. Condliffe ( Sheffield, United Kingdom), A. Lawrie ( Sheffield, United Kingdom), J. Wild ( Sheffield, United Kingdom), D. Kiely ( Sheffield, United Kingdom), A. Swift ( Sheffield, United Kingdom)
Risk status at selexipag initiation in pulmonary arterial hypertension (PAH): Insights from EXPOSURE S. Gaine (Dublin, Ireland), P. Escribano (Madrid, Spain), P. Biedermann (Allschwil, Switzerland), A. Muller (Allschwil, Switzerland), H. Sun (Allschwil, Switzerland), S. Söderberg (Umeå, Sweden), T. Lange (Regensburg, Germany)
Metabolic profiling of pulmonary vascular phenotypes in systemic sclerosis C. Simpson (Baltimore, United States of America), S. Mathai (Baltimore, United States of America), T. Kolb (Baltimore, United States of America), P. Hassoun (Baltimore, United States of America), S. Aja (Baltimore, United States of America), A. Roux (St. Petersburg, United States of America), D. Graham (St. Petersburg, United States of America), R. Damico (Baltimore, United States of America)
Gamma-Glutamyltransferase in pulmonary hypertension: A reliable biomarker? J. Lund (Giessen, Germany), A. Yogeswaran (Giessen, Germany), K. Tello (Giessen, Germany), N. Sommer (Giessen, Germany), J. Grimminger (Giessen, Germany), L. Harbaum (Hamburg, Germany), J. Hennigs (Hamburg, Germany), H. Klose (Hamburg, Germany), H. Ghofrani (Giessen, Germany), W. Seeger (Giessen, Germany), M. Richter (Giessen, Germany), H. Gall (Giessen, Germany)
mRNA sequencing of educated platelets generates a diagnostic biomarker for discrimination between pre- and post-capillary pulmonary hypertension. M. Arkani (Amsterdam, Netherlands), S. Jansen (Amsterdam, Netherlands), S. In'T Veld (Amsterdam, Netherlands), J. Smits (Amsterdam, Netherlands), E. Post (Amsterdam, Netherlands), K. Zwaan (Amsterdam, Netherlands), J. Ramaker (Amsterdam, Netherlands), F. S. De Man (Amsterdam, Netherlands), A. Vonk Noordegraaf (Amsterdam, Netherlands), M. Best (Amsterdam, Netherlands), T. Wurdinger (Amsterdam, Netherlands), H. Bogaard (Amsterdam, Netherlands)
Utility of D-Dimer for mortality prediction in patients at risk for pulmonary hypertension V. Foris (Graz, Austria), F. Prüller (Graz, Austria), G. Kovacs (Graz, Austria), A. Avian (Graz, Austria), P. Douschan (Graz, Austria), M. Herrmann (Graz, Austria), H. Olschewski (Graz, Austria)
Association between Metabolites Biomarkers and Pulmonary Hypertension:A Mendelian Randomization analysis D. Zhou (Guangzhou, China), J. Liao (Guangzhou, China), Y. Chen (Guangzhou, China), J. Wang (Guangzhou, China)
Impact of the new definition of precapillary pulmonary hypertension on patient disposition P. Rosenstock (Graz, Austria), K. Zeder (Graz, Austria), A. Avian (Graz, Austria), G. Bachmaier (Graz, Austria), P. Douschan (Graz, Austria), V. Foris (Graz, Austria), T. Sassmann (Graz, Austria), H. Olschewski (Graz, Austria), G. Kovacs (Graz, Austria)
Impact of the new hemodynamic classification in the diagnosis of pulmonary hypertensionReport from a pneumology based PH center K. Heinig-Menhard (Gauting, Germany), C. Stoleriu (Gauting, Germany), M. Heiss-Neumann (Gauting, Germany), E. Silbernagel (Gauting, Germany), M. Neiswirth (Gauting, Germany), J. Behr (Gauting, Germany), R. Göres (Munich, Germany), W. Gesierich (Munich, Germany), F. Reichenberger (Munich, Germany), F. Reichenberger (Munich, Germany)
CIPHER: a prospective, multicentre study for the identification of biomarker signatures for early detection of pulmonary hypertension L. Howard (London, United Kingdom), K. Chin (Dallas, United States of America), Y. Fong (Allschwil, Switzerland), C. Gargano (Allschwil, Switzerland), D. Stamatiadis (Allschwil, Switzerland), B. Maron (Boston, United States of America), I. Preston (Boston, United States of America), D. Quinn (Allschwil, Switzerland), S. Rosenkranz (Cologne, Germany), M. Toshner (Cambridge, United Kingdom), M. Wilkins (London, United Kingdom), D. Kiely (Sheffield, United Kingdom)
Feasibility of microRNA signatures for detection early stage pulmonary hypertension A. Waxman (Boston, United States of America), Y. Fong (Raritan, United States of America), T. Jatkoe (Raritan, United States of America), H. Cheng (Singapore, Singapore), L. Zhou (Singapore, Singapore), C. Bridges (Boston , United States of America)
Reliability of echo systolic pulmonary arterial pressure to detect new definition of pulmonary hypertension H. Gall (Giessen, Germany), A. Yogeswaran (Giessen, Germany), K. Tello (Giessen, Germany), N. Sommer (Giessen, Germany), H. Ghofrani (Giessen, Germany), W. Seeger (Giessen, Germany), M. Richter (Giessen, Germany)
Using parasternal electromyogram to measure neural respiratory drive in pulmonary hypertension P. Mccaughey (Glasgow (Glasgow), United Kingdom), M. Mcgettrick (Glasgow (Glasgow), United Kingdom), A. Maclellan (Glasgow (Glasgow), United Kingdom), M. Brewis (Glasgow (Glasgow), United Kingdom), C. Church (Glasgow (Glasgow), United Kingdom), M. Johnson (Glasgow (Glasgow), United Kingdom)
Prevalence of hyperventilation syndrome in pulmonary arterial hypertension E. Jutant (Paris, France), C. Malka Ruimy (Paris, France), A. Beurnier (Paris, France), A. Belguendouz (Paris, France), M. Preda (Paris, France), X. Jaïs (Paris, France), L. Savale (Paris, France), G. Garcia (Paris, France), M. Humbert (Paris, France), O. Sitbon (Paris, France), D. Montani (Paris, France)